HSIC

Business Profile & Competitive Position

Henry Schein, Inc. operates in the Healthcare sector under the Medical - Distribution industry. It is a health care solutions company serving primarily office-based dental and medical practitioners, plus alternate sites of care, through three reportable segments. The Global Distribution and Value-Added Services segment distributes dental and medical merchandise, equipment, repair services, pharmaceuticals, vaccines, and value-added services; Global Specialty Products manufactures dental implants, biomaterials, endodontic, orthodontic, and orthopedic products; and Global Technology develops practice-management software, e-services, and other technology-enabled products for health care providers.

The financial profile is characteristic of a scaled wholesaler. A net margin of 3.0% is thin, reflecting the buy-and-sell economics of distribution. ROE of 12.4% is more encouraging: it shows Henry Schein generating a low-double-digit return on shareholder equity despite that thin margin, which usually signals disciplined working-capital management, a mix of private-label and specialty products, and recurring revenue streams such as software subscriptions and equipment service. The physical scale—38 distribution centers covering more than 5.4 million square feet, 17 manufacturing facilities covering 0.6 million square feet, more than 300,000 stocked products, roughly 150,000 cartons shipped daily, and 127 equipment sales and service centers worldwide—acts as a logistical barrier that smaller competitors cannot easily replicate. The Technology segment's active user base of approximately 95,000 practices and 324,000 consumers as of December 27, 2025 provides a recurring, high-attachment platform. Combined, those numbers point to a moderate competitive moat built on route density, breadth of assortment, and embedded practice-management software rather than exceptional pricing power.

Financial Posture

With a market capitalization of $10.2 billion and a trailing P/E of 26.0, Henry Schein is priced like a compounder rather than a deep-value commodity distributor. That multiple sits well above what a 3.0% net margin would usually command on its own, so the valuation is clearly relying on the 12.4% ROE, low cyclicality, and the expectation that software and specialty growth can expand returns over time. The stock's beta of 0.81 means it has historically moved less than the broader market, consistent with a non-discretionary, office-based-customer business. At the current snapshot, HSIC trades at $89.8 with an RSI of 58.9 and a 50-day EMA of $86.37, so the price sits above its near-term moving average without being technically overbought. The combination of a mid-20s P/E and a sub-4% margin leaves limited tolerance for operational disappointment; multiple compression could follow quickly if margin or growth expectations shift.

Strategic Priorities & Outlook

Henry Schein's most recent 10-K filings outline an operational blueprint organized around several explicit initiatives. The BOLD+1 plan is intended to build complementary software, specialty-products, and services businesses in higher-growth adjacencies. Operationally, the company is pursuing "One Distribution," designed to deliver an exceptional customer experience while driving efficiency and growth. In parallel, "One Schein" is meant to broaden and deepen customer relationships across the portfolio. Finally, management is driving digital transformation both for its customers and internally at Henry Schein.

These priorities map cleanly onto the reported numbers. The infrastructure already in place—38 distribution centers, 17 manufacturing facilities, more than 300,000 products, and about 150,000 cartons shipped daily—is the asset base management is trying to optimize through "One Distribution." The software base of roughly 95,000 practices and 324,000 consumers is the cross-sell foundation for "One Schein." Specialty products and services are the BOLD+1 growth levers. In short, the strategic story is less about entering new end markets and more about extracting more revenue per customer, per square foot, and per route stop.

Macro & Geopolitical Exposure

As a Medical - Distribution company, Henry Schein's economics are tied to the broader health care ecosystem rather than any single discretionary trend. Key macro exposures include regulation and reimbursement policy: changes in Medicaid, Medicare, dental insurance reimbursement rates, or state-level scope-of-practice rules directly affect the purchasing power of office-based practitioners. Trade policy and tariffs also matter because gloves, masks, implants, orthodontic supplies, and small equipment are often sourced or assembled globally; any escalation in U.S.-China or transatlantic trade friction can alter landed costs. Currency risk is inherent too, since distributors with global manufacturing and customer bases convert revenue and costs across multiple currencies. Supply-chain and logistics costs—fuel, freight, and warehousing labor—flow through a thin 3.0% net margin. Pharmaceutical and vaccine distribution adds cold-chain and regulatory compliance dimensions. Demand is also a function of patient visit volumes and the timing of elective procedures, both of which are sensitive to public-health conditions and provider capacity.

Recent Developments

The most recent headlines, all from late August 2026, frame HSIC as a value name with a mixed execution narrative. On August 28, defenseworld.net reported that Bank of New York Mellon Corp purchased 505,999 shares, a notable institutional accumulation signal heading into the fall. On August 25, Zacks.com ran a comparison piece, "HSIC vs. SAUHY: Which Stock Is the Better Value Option?" That was followed on August 21 by another Zacks article, "Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term." The series concluded on August 19 with a more cautionary headline: "Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?"

Together, those four items capture the current tension: institutional buyers are adding exposure, sell-side commentary is highlighting value, but the same sources are flagging execution risk. The BOLD+1, One Distribution, and One Schein initiatives from the 10-K are the likely source of that execution debate—turning a traditional distributor into a higher-margin, more integrated health care solutions company is operationally difficult, even with 38 distribution centers and a 95,000-practice software footprint.

Earnings Behavior & Post-Earnings Drift

Henry Schein has a solid recent earnings record, but the stock's reaction tells a more complicated story. Over the last eight reported quarters, HSIC beat the consensus estimate six times, a 75% beat rate, with an average positive surprise of 2.9%. Yet the average five-day price move after those reports is -2.05%, classified as a downward post-earnings drift. In other words, the company has delivered bottom-line upside more often than not, and the market has still tended to sell the news in the days that followed.

The most recent quarters illustrate that pattern. On August 4, 2026, HSIC reported EPS of $1.27 against an estimate of $1.24, a 2.4% beat; the stock rose 0.54% the next day but gave most of it back, ending the five-day window up only 0.08%. The May 5, 2026 quarter was a much larger beat—actual EPS of $1.32 versus a $1.20 estimate, a 10% surprise—but the next-day move was -2.6% and the five-day move was -6.75%. The February 24, 2026 quarter delivered $1.34 versus $1.30 (3.1% surprise) and was met with a -1.73% one-day move and a -3.77% five-day move. Only the November 4, 2025 report bucked the trend: $1.38 versus $1.27 (8.7% surprise), with a 0.56% next-day gain and a 2.25% five-day gain. The next report is scheduled for November 3, 2026, before the open, with the current consensus EPS estimate at $1.34.

For traders, the implication is that beating estimates has not guaranteed upside price follow-through. Even strong quarterly results have been followed by post-earnings selling pressure, which suggests expectations may be reset higher before the print and/or the market is more focused on forward guidance and margin trajectory than on the headline beat.

For a deeper dive into how institutional analysts currently view these cross-currents—covering the latest consensus estimates, rating changes, and the full spectrum of broker views—look at the full institutional verdict for HSIC.